{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:44:36Z","timestamp":1761518676746},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1454,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1998,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>The high\u2010dose dexamethasone (dex) suppression test of cortisol secretion (8\u00d72\u2003mg dex over two days or 8\u2003mg overnight) is a mainstay in the differential diagnosis of Cushing's syndrome (CS). In some patients with pituitary Cushing's disease (CD), however, plasma cortisol is not suppressed to &lt;50% of control by 8\u2003mg of dex. We therefore hypothesized that a higher dose of dex might produce more effective suppression of cortisol secretion in CD.<\/jats:p><\/jats:sec><jats:sec><jats:title>DESIGN AND SUBJECTS<\/jats:title><jats:p>We routinely tested the diagnostic efficacy of a very high dose of dex (32\u2003mg, i.e. 4\u00d78\u2003mg in 24 hours) in comparison with the 8\u2003mg overnight dex test in a population of patients with CD, in which an unusually high percentage was refractory to 8\u2003mg dex. End points were the suppression of plasma cortisol, plasma ACTH and urinary free cortisol (UFC) to &lt;50% of control. Corticotrophin releasing hormone (human CRH) tests were also performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Eleven out of 26 (11\/26) patients with CD (42%), among them six with pituitary macroadenomas, failed to show suppression of plasma cortisol after 8\u2003mg dex. Five out of 19 patients (26%) with CD failed to suppress after 32\u2003mg dex. Only 3\/19 (16%) failed to suppress UFC after 32\u2003mg dex. In non\u2010 pituitary CS (<jats:italic>n<\/jats:italic>=11), only one patient with macronodular adrenal hyperplasia showed significant suppression of plasma cortisol, but not UFC, after 32\u2003mg dex. ACTH suppression after 8 or 32\u2003mg dex was often less pronounced than that of cortisol and was of no diagnostic value. Cortisol stimulation by 23% after hCRH injection differentiated 100% of patients with CD from other forms of CS.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>In this series, the hCRH test was the most reliable test for the differential diagnosis of Cushing's syndrome. The 32\u2003mg dexamethasone test with measurement of urinary free cortisol was clearly superior to the 8\u2003mg test and to other aspects of the very high dose dexamethasone test. It can be recommended for \u2018non\u2010suppressible\u2019 patients with ACTH\u2010dependent Cushing's syndrome and can be performed on outpatients.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2265.1998.00345.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:35:20Z","timestamp":1047378920000},"page":"45-51","source":"Crossref","is-referenced-by-count":17,"title":["A very high dose dexamethasone suppression test for differential diagnosis of Cushing's syndrome"],"prefix":"10.1111","volume":"48","author":[{"family":"Al\u2010Saadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Diederich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Oelkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196708242770814"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-97-1-21"},{"key":"e_1_2_5_4_2","first-page":"175","article-title":"Cushing's syndrome. An evaluation of the clinical usefulness of free urine cortisol and other urinary steroid measurements in diagnosis","volume":"165","author":"Burke C.W.","year":"1973","journal-title":"Quarterly Journal of Medicine"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30412-2"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1987.66.2.0204"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(79)90097-0"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1990.tb00462.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.2.418"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0100025"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-3-211"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01660959"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90113-3"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-76-3-112-6-434"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90443-9"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-20-12-1539"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196708242770804"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(88)90116-7"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-6-487"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00184788"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-6-862"},{"key":"e_1_2_5_22_2","first-page":"370","article-title":"Primary adrenocortical micronodular adenomatosis causing Cushing's syndrome. Effects of ketoconazole on steroid production and in vitro performance of adrenal cells","volume":"113","author":"Oelkers W.","year":"1986","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199109263251301"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199109263251309"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(80)90375-7"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30373-6"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-2-180"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1998.00345.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1998.00345.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1998.00345.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:59:30Z","timestamp":1698454770000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.1998.00345.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["10.1046\/j.1365-2265.1998.00345.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.1998.00345.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,1]]}}}